论文部分内容阅读
目的： 评价伊曲康唑冲击疗法治疗由皮肤癣菌、酵母菌和霉菌引起的甲真菌病的有效性、安全性和耐受性。方法： 采用冲击疗法， 连续服用伊曲康唑（４００ ｍｇ／ｄ） １ 周后， 停药３周为１ 个疗程。指甲真菌病服药２ 个疗程； 趾甲真菌病服药３ 个疗程。观察疗程结束、停药３个月及停药６ 个月时指（ 趾） 甲真菌病的临床治愈率和真菌学治愈率。结果： 疗程结束时、停药后３ 个月及停药后６ 个月时指甲真菌病的临床治愈率分别为２５ ％ 、８５ ％ 和９０ ％ ， 真菌学治愈率分别为６５ ％ 、９０ ％ 和９５ ％ ； 趾甲真菌病的临床治愈率分别为１６－６ ％ 、６３－３ ％ 和８６－７ ％ ， 真菌学治愈率分别为５６－７ ％ 、８３－３ ％ 和９０ ％ 。疗程结束后， 随时间延长治愈率不断提高， 停药后６ 个月达最高。指甲真菌病的治愈率高于趾甲真菌病； 真菌学治愈率高于临床治愈率。未发现严重不良反应。停药后６ 个月时复发率为６ ％ 。结论： 伊曲康唑为广谱抗真菌药， 冲击疗法治疗甲真菌病具有疗效高、安全性好、耐受性高以及费用低廉的特点。
PURPOSE: To evaluate the efficacy, safety and tolerability of itraconazole impact therapy in the treatment of onychomycosis caused by dermatophytes, yeasts and molds. Methods: The impact therapy, continuous administration of itraconazole (400 mg / d) for 1 week, withdrawal 3 weeks for a course of treatment. Nail mycosis medication 2 courses; toenail mycosis medication 3 courses. The clinical cure rate and mycological cure rate of toenail onychomycosis were observed at the end of the course of treatment, withdrawal of 3 months and withdrawal of 6 months. Results: At the end of treatment, the clinical cure rates of nail mycosis were 25%, 85% and 90% at 3 months after drug withdrawal and 6 months after drug withdrawal respectively. The cure rates of mycology were 65%, 90% and 95%. The clinical cure rates of toenail mycosis were 16-6%, 63-3% and 86-7% respectively. The mycological cure rates were 56-7%, 83-3% and 90% respectively. After the end of treatment, with the extension of the cure rate continues to rise, up to 6 months after stopping the highest. The cure rate of nail mycosis was higher than that of toenail mycosis; the cure rate of mycology was higher than the clinical cure rate. No serious adverse reactions were found. The relapse rate was 6% at 6 months after discontinuation. CONCLUSION: Itraconazole is a broad-spectrum antifungal agent. It has the characteristics of high curative effect, good safety, high tolerance and low cost in the treatment of onychomycosis with impact therapy.